@ionade I am not sure your view on courage or brains is respectful. Everybody has a risk tolerance and junior pharma companies are high risk. Most at our stage will fail.Published success rates of academic drugdiscovery and development are 75% at phase I, 50% at phase II, 59% at phaseIII, and 88% at the new drug application/biologics license application (NDA/BLA)phase. Multiply all of those together and the probability of success sits at 19%. Therefore we are likely to fail. The reward has to reflect the high probability that this will be a dud.
What do you see that tilts these odds in our favor and warrants taking the risk? BTW I am invested and have my own views on why the risk is worth taking and lower than these whole of industry success rates.
If we get to 4000mg/kg with tolerable toxicity our chances of success go up to 26% without another variable changing. Still pretty risky.
@ionade I am not sure your view on courage or brains is...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $83.62M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 28.5¢ | $37.25K | 127.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 161128 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 9666 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |